Lv6
2170 积分 2022-02-15 加入
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
2天前
已完结
Is there a place for engineered immune cell therapies in autoimmune diseases?
9天前
已完结
Less phagocytosis of viral vectors by tethering with CD47 ectodomain
10天前
已完结
Engineered retroviruses map ligand–receptor interactions
23天前
已完结
Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
1个月前
已完结
Dual targeting CAR-T cells for B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin lymphoma
1个月前
已关闭
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
1个月前
已完结
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
1个月前
已关闭
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
1个月前
已关闭
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
1个月前
已关闭
皖公网安备34019202002308
